A
Asterios Karagiannis
Researcher at Aristotle University of Thessaloniki
Publications - 371
Citations - 9810
Asterios Karagiannis is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Metabolic syndrome & Arterial stiffness. The author has an hindex of 49, co-authored 354 publications receiving 8704 citations. Previous affiliations of Asterios Karagiannis include University of London & University College London.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Vasilios G. Athyros,Konstantinos Tziomalos,Thomas D. Gossios,Theodora Griva,Panagiotis Anagnostis,Konstantinos Kargiotis,Efstathios D. Pagourelias,Eleni Theocharidou,Asterios Karagiannis,Dimitri P. Mikhailidis +9 more
TL;DR: Statin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild-to-moderately abnormal liver tests that are potentially attributable to non-alcoholic fatty liver disease.
Journal ArticleDOI
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Panagiotis Anagnostis,Vasilios G. Athyros,Konstantinos Tziomalos,Asterios Karagiannis,Dimitri P. Mikhailidis +4 more
TL;DR: The present review summarizes the evidence on the potential role of cortisol in the pathogenesis of MetS and discusses new therapeutic approaches for patients with MetS, which may be partly associated with chronic stress and/or low birth weight.
Journal ArticleDOI
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Vasilios G. Athyros,Dimitri P. Mikhailidis,Triandafillos P. Didangelos,Olga Giouleme,Evangelos Liberopoulos,Asterios Karagiannis,Anna I. Kakafika,Konstantinos Tziomalos,Andrew K. Burroughs,Moses Elisaf +9 more
TL;DR: Multifactorial intervention in MetS patients with both biochemical and ultrasonographic evidence ofNAFLD offsets surrogate markers of NAFLD (i.e. elevated aminotransferase plus echogenic liver).
Journal ArticleDOI
Gonadal dysfunction in systemic diseases
TL;DR: A brief review of the most common disturbances seen in the main systemic diseases of gonadal dysfunction will be discussed.
Journal ArticleDOI
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Vasilios G. Athyros,Theodore K. Alexandrides,Helen Bilianou,Evangelos Cholongitas,Michael Doumas,Emmanuel S. Ganotakis,John A. Goudevenos,M.S. Elisaf,Georgios Germanidis,Olga Giouleme,Asterios Karagiannis,Charalambos Karvounis,Niki Katsiki,Vasilios Kotsis,Jannis Kountouras,Evangelos Liberopoulos,Christos Pitsavos,Stergios A. Polyzos,Loukianos S. Rallidis,Dimitrios J. Richter,Apostolos Tsapas,Alexandros D. Tselepis,Konstantinos Tsioufis,Konstantinos Tziomalos,Themistoklis Tzotzas,Themistoklis G. Vasiliadis,Charalambos Vlachopoulos,Dimitri P. Mikhailidis,Christos S. Mantzoros +28 more
TL;DR: Physicians should consider using a PPARgamma agonist, such as pioglitazone, or statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD.